Mitoxantrone is a part of many chemotherapeutic regimens, therefore, when choosing the route of administration, regimen and dosage in each individual case, one should be guided by the data of the special literature.
The drug is administered intravenously slowly, for at least 5 minutes or intravenously drip for 15-30 minutes. It is preferable to inject Oncotron into the tube of the infusion system slowly against a background of rapid infusion with 0.9% sodium chloride solution or 5% glucose solution.
Intrathecal, intraarterial, intramuscular, subcutaneous injection of the drug is prohibited!
The maximum total dose of Oncotron is 200 mg / m2 surface of the body.
When breast cancer, non-Hodgkin's lymphoma, liver cancer and ovarian cancer in monotherapy Oncotron is used in a dose of 14 mg / m2 1 time in 3 weeks. In patients who received chemotherapy earlier, and also when combined with other antitumour agents, the dose of the drug is reduced to 10-12 mg / m2. When repeated courses of Oncotron dose are selected taking into account the degree of severity and duration of oppression of bone marrow hematopoiesis.
In the case of a decrease in the number of neutrophils at previous courses <1500 and / or platelets <50,000 cells / μl of blood, the dose of oncotron is reduced by 2 mg / m2, with a decrease in the number of neutrophils <1000 and / or platelets <25,000 cells / μl of blood, subsequent Oncotron doses are reduced by 4 mg / m2.
In the treatment of acute non-lymphoblastic leukemia In adults, in order to induce remission, the Oncotron is administered at a dose of 10-12 mg / m2 daily for 5 days to a total dose of 50-60 mg / m2. It is possible to use high doses of Oncotron 14 mg / m2 and more daily for 3 days.
For treatment hormone-resistant prostate cancer Oncotron is prescribed in a dose of 12-14 mg / m2 1 every 21 days in combination with daily intake of low doses of glucocorticosteroids (prednisolone 10 mg / day or hydrocortisone 40 mg / day).
When intrapleural instillation with metastases in the pleura (for breast cancer and non-Hodgkin's lymphomas) the recommended single dose is 20-30 mg. For intrapleural instillation Oncotron is diluted in 50 ml of 0.9% sodium chloride solution. Before the beginning of therapy evacuate, whenever possible, pleural exudate. Oncotron diluted in 50 ml of 0.9% sodium chloride solution is warmed to body temperature and injected slowly for 5-10 minutes, without the use of effort. The delay period of the first dose of Oncotron in the pleural cavity is 48 hours. During this period, patients should move to ensure optimal intrapleural distribution of the drug. After the end of this time (48 hours), the pleural cavity is re-drained. If the amount of effusion is less than 200 ml, the first treatment cycle is stopped. With an effusion volume exceeding 200 ml, a repeated instillation of 30 mg of Oncotron is prescribed.Before carrying out the repeated instillation of the drug, hematological parameters should be monitored. A second dose of Oncotron may remain in the pleural cavity. The maximum dose for one treatment cycle is 60 mg. If the number of neutrophils and platelets is within normal limits, intrapleural instillation can be repeated after 4 weeks.
For 4 weeks before and 4 weeks after intrapleural administration of Oncotron, systemic cytotoxic therapy should be avoided.